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lntracoronary stenting has been introduced as an 
adjunct to balloon angioplasty aimed at overcom- 
ing its limitations, namely acute vessel closure and 
late restenosis. This study reports the first experi- 
ence with the WiktoP stent implanted in the first 
50 consecutive patients. All patients had resteno- 
sis of a native coronary artery lesion after prior 
balloon angioplasty. The target coronary artery 
was the left anterior descending artery in 26 pa- 
tients, the circumflex artery in 7 patients and the 
right coronary artery in 17 patients. The implan- 
tation success rate was 98% (49 of 50 patients). 
There were no procedural deaths. Acute or sub- 
acute thrombotic stent occlusion occurred in 5 pa- 
tients (10%). All 5 patients sustained a nonfatal 
acute myocardial infarction. Four of these patients 
underwent recanalization by means of balloon an- 
gioplasty; the remaining patient was referred for 
bypass surgery. A major bleeding complication oc- 
curred in 11 patients (22%): groin bleeding neces- 
sitating blood transfusion in 6, gastrointestinal 
bleeding in 3 and hematuria in 2. Repeat angiog- 
raphy was performed at a mean of 5.6 f 1.1 
months in all but 1 patient undergoing implanta- 
tion. Restenosis, defined by a reduction of 20.72 
mm in the minimal luminal diameter or a change in 
diameter stenosis from < to >_SO%, occurred in 
20 (45%) and 13 (29%) patients, respectively. In 
this first experience, the easiness and high techni- 
cal success rate of Wiktor stent implantation are 
overshadowed by a high incidence of subacute 
stent occlusion and bleeding complications. Al- 
though direct comparison with balloon angioplasty 
regarding the incidence of subsequent restenosis 
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rate is not possible, the experience reported in 
this study compares favorably with data reported 
in other published reports. 
(Am J Cardiol 1992;69:598-602) 
P ercutaneous transluminal coronary balloon an- gioplasty (PTCA) has established its role as a nonsurgical revascularization procedure in select- 
ed patients with obstructive coronary artery disease. 
Gained operator experience and improved catheter 
technology has resulted in a high immediate success 
rate and a low incidence of complications.’ These favor- 
able initial results are compromised by the unpredict- 
able problem of late restenosis, occurring in 20 to 40% 
of the patients after successful PTCA.2-5 Furthermore, 
there is some evidence that the recurrence of subsequent 
restenosis after repeat PTCA increases with the number 
of repeat interventions. 6-9 Intracoronary stents are one 
of the new technologies that (along with pharmacologic 
interventions, atherectomy and laser techniques) have 
entered clinical testing to address this problem.lO Re 
cently, the first experience with the self-expandable 
Wallstent@ and the balloon expandable Palmaz-Schatz@ 
stent have been reported.“J2 The stent used in this 
study is the Medtronic WiktorTM stent which, in contrast 
to the Wallstent and the Palmaz-Schatz stent, is not a 
mesh-made stainless teel device but a coil-like prosthe 
sis made of a single loose interdigitating tantalum wire 
formed into a sinusoidal wave and configured as a helix. 
This loose configuration may offer less scaffolding prop- 
erties compared with the other 2 stents. Therefore, the 
purpose of this study was to assess the immediate and 
long-term clinical and angiographic results following 
Wiktor stent implantation in the first 50 consecutive pa- 
tients with restenosis following balloon angioplasty of a 
native coronary artery lesion. 
METHODS 
Patients: The study group consisted of the first 50 
consecutive patients in whom a single Wiktor stent im- 
plantation was attempted (Table I). All patients had re- 
currence of angina with objective vidence of ischemia 
due to restenosis of a native coronary artery lesion fol- 
lowing PTCA. A first restenosis was documented in 33 
patients, a second restenosis n 13 patients and a third in 
4 patients. The dilated and stented coronary artery was 
the left anterior descending artery in 26 patients (52%), 
the circumflex artery in 7 patients (14%) and the right 
coronary artery in 17 patients (34%). A written in- 
formed consent was required for every patient. The 
study protocol was approved by the ethics committee of 
the individual hospitals. The stents used in this study 
are shown in Figures 1 and 2. They are described in 
detail elsewhere as well as the drug protocol associated 
with stent implantation. 11,13 The angiograms were ana- 
lyzed using automated edge-detection as previously de- 
scribed.14J5 
End points: Primary clinical end points were death, 
myocardial infarction, bypass surgery or repeat inter- 
vention and bleeding complications. All deaths were 
considered cardiac, unless an unequivocal noncardiac 
cause could be established. The primary angiographic 
end point was the change in minimal luminal diameter 
at the dilated and stented segment at 6 months relative 
to the baseline. If a revascularization procedure involv- 
ing the stented segment had been performed before 6 
months repeat angiography, the last angiogram before 
this intervention was used to obtain follow-up values, 
irrespective of the timing of repeat PTCA (hours, days 
or weeks). The secondary angiographic end point was 
the incidence of restenosis defined according to the fol- 
lowing criteria: First, a continuous approach was used in 
which restenosis was defined by a reduction of 10.72 
mm in the minimal luminal diameter at follow-up. This 
change in minimal luminal diameter has been found to 
be a reliable indicator of angiographic progression of 
vessel narrowing. This value takes into account he limi- 
tations of coronary angiographic measurements and 
represents wice the long-term variability of repeat mea- 
surements of a coronary artery obstruction with the 
Cardiovascular Angiographic Analysis System. l5 Sec- 
ond, a categorical approach was used in which an in- 
crease in diameter stenosis of <50% immediately after 
stent implantation to 250% at follow-up was used as a 
cutoff point to define restenosis. This criterion was se- 
lected since common clinical practice has continued to 
express lesion severity as a percentage of stenosis. 
Statistics: Values obtained by quantitative angio- 
graphic analysis are expressed as mean f SD. The 
means for each angiographic variable before PTCA, af- 
ter PTCA, immediately after stent implantation and at 
follow-up were compared by analysis of variance. If sig- 
nificant differences were found, 2-tailed t tests were ap- 
plied to paired data. A statistical probability of <0.05 
was considered significant. In the patient with the miss- 
FIGURE 1. lMedtm& W”lkor stent meuntedenacenventiond FIGURE 2. Difference between the mean diameter of the bal- 
polyethylene baUoan wben deifated (top panel) and Mated loon when fully Mated and stented segment immediate& af- 
(bottom panel). ter implantation. 
TABLE I Clinical Characteristics 
No. of patients 
Age (mean ir SD, yrs) 
Men 
Functional class* 
I 
II 
III 
IV 
Systemic hypertension 
Cholesterol > 200 mg % 
Cigarette smokers 
Diabetes mellitust 
*According to Canadian Cardiovascular Society. 
tAll non~insulin-dependent. 
50 
55 + 9 
44 
10 
6 
14 
20 
7 
7 
17 
6 
ing follow-up angiogram and no clinical evidence of re- 
stenosis, imputation of the minimal luminal diameter at 
follow-up was performed: the minimal luminal diameter 
at follow-up of this patient was calculated by subtract- 
ing the mean change of the minimal luminal diameter 
of the entire study population from the value of the 
minimal luminal diameter immediately after stent im- 
plantation of this particular patient. 
RESULTS 
Clinical results: The implantation success rate was 
98% (49 of 50 attempted implants). In 1 patient, the 
stent could not be delivered at the target site due to the 
inability to cross a tortuous proximal right coronary ar- 
tery. There were no procedural related deaths. How- 
ever, subacute thrombotic stent occlusion occurred in 5 
patients (10%) while still in the hospital. The occur- 
rence to this thrombotic event with respect o the im- 
plantation was as follows: day 0 = 1 patient, day 1 = 1 
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TABLE II Changes in Minimal Luminal Diameter After Wiktor Stent Implantation 
At Follow-Up 
Minimal luminal diameter 
(mm) 
Diameter stenosis (%) 
Pts. Without 
Subacute 
Before After After Stem All Pts. Occlusion 
PTCA PTCA Implantation (n = 49) (n = 44) 
1.09 r 0.26 1.80 f 0.32 2.45 r 0.35 1.59 t 0.79 1.78 2 0.60 
61 +-9 342 11 18 f 7 45 + 25 39 + 18 
- p < 0.00001- -p < O.OOl- - p < 0.00001- 
-p < 0.00001 
All parameters are expressed as mean 2 SD. 
PTCA = percutaneous transluminal coronary angioplasty. 
patient, day 4 = 1 patient, and day 5 = 2 patients. Four 
patients underwent recanalization by means of conven- 
tional balloon angioplasty. In 1 of these patients adjunc- 
tive thrombolytic therapy was used. In the remaining 
patient, repeat PTCA was not attempted because retro- 
spective analysis of the implantation angiogram re- 
vealed incomplete stent expansion. This patient was re- 
ferred for emergency bypass urgery. All 5 patients us- 
tained a nonfatal acute myocardial infarction (mean f 
SD, creatine phosphokinase 1,797 f 1,849 U/liter). A 
major bleeding complication occurred in 11 patients 
(22%): 6 patients sustained a groin hematoma necessi- 
tating blood transfusion, 3 patients had a gastrointesti- 
nal bleeding (2 duodenal ulcers, 1 intestinal polyps) and 
2 patients had hematuria. One patient had an infected 
pharyngeal hematoma caused by acenocoumarol thera- 
py at 3 months after implant. 
During follow-up, 1 patient died 3 months after stent 
implantation following prostate surgery. This patient 
had a history of bypass surgery, mitral valve replace- 
ment and multiple PTCA’s. Because of severe disabling 
heart failure, he was screened for heart transplantation. 
During this period, a prostate adenoma was found and 
surgically removed. The second day after surgery, he 
died because of heart failure. Although necropsy was 
not performed, death was not considered stent-related 
because there was no clinical evidence of restenosis. No 
patient sustained an acute myocardial infarction. Three 
patients (6%) underwent bypass surgery (2 patients 3.5 
months and 1 patient 6 months after the stent implanta- 
tion). There was a significant improvement in function- 
al class at 6-month follow-up. Before stent implantation, 
10 patients were in class I, 6 in class II, 14 in class III 
and 20 in class IV, according to the Canadian Cardio- 
vascular Society. At follow-up, 34 patients were in class 
I, 9 in class II, 4 in class III and 3 in class IV. 
Angiographic results: Wiktor stent implantation re- 
sulted in a further significant increase in minimal lumi- 
nal diameter, from 1.80 f 0.32 mm immediately fol- 
lowing balloon angioplasty to 2.45 f 0.35 mm immedi- 
ately after stent implantation. This was associated with 
a reduction in diameter stenosis from 34 f 11 to 18 f 
7% (Table II). There was no change in the reference 
diameter before and after PTCA (2.81 f 0.48 and 2.80 
f 0.48 mm, respectively, p = not significant). However, 
there was a significant increase after stent implantation 
(2.98 f 0.42 mm, p <O.OOOOl), which was confirmed at 
follow-up (2.91 f 0.55 mm). In most patients the mea- 
sured diameter of the balloon when fully inflated was 
higher than the measured iameter of the stent (Figure 
2). During maximal inflation the mean diameter of the 
balloon for the total study group was 2.98 f 0.44 mm. 
The mean diameter of the stented segment immediately 
after implantation was 2.88 f 0.43 mm. This implies a 
recoil of 0.10 f 0.36 mm (p <0.03). 
Repeat angiography was performed in all patients 
with successful stent implantation (49 patients), except 
in 1, who died 3 months after stent implantation follow- 
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ing prostate surgery. There was no clinical evidence of 
restenosis in this patient. The mean time interval be- 
tween stent implantation and control study was 5.6 f 
1.1 months. Overall, the minimal luminal diameter was 
found to have decreased from 2.45 f 0.35 to 1.59 f 
0.79 mm (p <O.OOOOl). The percentage of stenosis had 
increased from 18 f 7 to 45 f 25% (p <O.OOOl, Table 
II). When only patients without clinical evidence of sub- 
acute vessel closure during hospital stay (44 patients) 
were included, the minimal luminal diameter and per- 
centage of stenosis were 1.78 f 0.60 mm and 39 f 
18%, respectively (Table II). Figure 3 displays the cu- 
mulative distribution of the minimal luminal diameter 
and its changes (immediately after balloon angioplasty 
and stent implantation and at follow-up). The addition- 
al increase in minimal luminal diameter immediately 
after stent implantation is lost at follow-up. 
The incidence of restenosis depended on the delini- 
tion used. When a change of 10.72 mm in minimal 
luminal diameter was used as the criterion, restenosis 
was observed within the stent in 19 patients (43%) and 
in the segment immediately distal to the stent in 1 (2%) 
of the 44 patients without clinical evidence of subacute 
stent occlusion during hospital stay. Of these 44 pa- 
tients, the percentage of stenosis at follow-up had in- 
creased to 250% within the stent in 12 (27%) and in the 
segment distal to the stent in 1 (2%). Therefore, the 
total restenosis rate was 45% according to the 0.72 mm 
criterion and 29% according to the 50% diameter steno- 
sis criterion (Figure 4). 
DISCUSSION 
Clinical results: Intracoronary stents are currently 
being tested in clinical practice to reduce the incidence 
of acute vessel occlusion and restenosis following bal- 
loon angioplasty. Several stems are available, each with 
its own specific design, composition and physicochemi- 
cal behavior once implanted. Implanting foreign body 
material implies an increased risk for acute thrombosis. 
Therefore, a stringent anticoagulation protocol is man- 
datory. Despite the protocol previously described, a 
thrombotic subacute stent occlusion occurred in 5 pa- 
tients (10%). Three of these patients did not receive 
dextran and 1 patient was not properly treated with 
acenocoumarol. Of the 44 patients without clinical evi- 
dence of subacute stent occlusion during hospital stay, 
only 6 (14%) did not receive dextran. Unfortunately, 
since central assessment of anticoagulation was not per- 
formed, the exact role of the failure of anticoagulation 
with respect o subacute thrombotic stent occlusion can- 
not be elucidated. Although it is tempting to speculate 
that suboptimal anticoagulation may be the main cause 
of stent occlusion, other pathophysiologic mechanisms 
also may be involved. Before stent implantation, balloon 
angioplasty is performed to facilitate stent delivery. The 
disruptive action of the balloon may cause intimal dis- 
section, which in turn may be the primary cause of an 
ensuing thrombotic event. Furthermore, patients’ relat- 
ed factors such as acute ischemic syndromes, procedure- 
related factors such as technical difficult stent implanta- 
tion and angiographic related factors such as small 
vessel size and total occlusion may predispose to throm- 
botic stent occlusion. In this study group, no difference 
in vessel size was seen in patients with and without sub- 
acute stent occlusion (reference diameter 2.8 f 0.4 and 
2.8 f 0.5 mm, respectively (p = not significant). The 
reported subacute stent occlusion rate compares very fa- 
vorably with the initial Wallstent experience (20% in 
105 patients), but is similar to the subacute occlusion 
rate following the extended Wallstent experience (12% 
in an additional 160 patients). l 1,16 However, it contrasts 
sharply with the incidence of 0.6% following Palmaz- 
Schatz stent implantation. l2 True comparison is not 
possible because the studies differ in methods for pa- 
tient selection, indication for stent implantation and 
type of vessel stented. Furthermore, the very low inci- 
dence of 0.6% reported by Schatz, has not been con- 
firmed by a recent study, using the same device.17 In 
this latter study, an incidence of 16% is reported. Proba- 
bly, the incidence of subacute stent occlusion may be 
reduced by a more detailed coagulation monitoring. In- 
deed, recent work indicates that measurement of pro- 
thrombin fragment 1 + 2 and its changes after stent 
implantation may be predictive for subacute thrombotic 
stent occlusion.‘8 
Another matter of concern is the risk of bleeding, 
inherently associated with aggressive anticoagulation. 
The incidence of bleeding is negligible after PTCA but 
is substantial when a combination of intravenous and 
4 
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FIGURE 4. Changes in the minimal luminal diameter (MLD) at 
foUow-up (F/U) after wilder stent implantation in native coro- 
nary arteries. The diameter of each segment immediately after 
stent implantation is plotted against the diameter at fdlow-up. 
The lines on each side of the line of identity (diagona/) repre- 
sent twii the variability (95% confidence interval) of *Ii- 
cate measurements (a change of LO.72 mm). Df the 49 pa- 
tknts,5(10%)sustainedasdacute stenl occlusion @CCL.) 
(X-axis). In the remaining 44 patients, restenosis was ob- 
served in 20 patii (45%) according to the 0.72 mm criteri- 
en and in 13 patients (29%) according to the 50% diameter 
stenosis (DS) criterion. 
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oral anticoagulant drugs are administered.12 The most 
serious bleeding complication is intracranial hemor- 
rhage, which occurred in 1 of 174 patients following 
Palmaz-Schatz stent implantation and in 3 of 265 pa- 
tients following Wallstent implantation.12J6 Another as- 
pect to be considered regarding anticoagulation is the 
longer period of hospitalization, which in turn increases 
the overall costs of the procedure.19 In this study, the 
hospital stay was (mean f SD) 11.8 f 7.4 days for the 
entire study population. 
Angiographic results: The smaller mean diameter of 
the stented segment (2.88 f 0.43 mm) compared with 
the measured diameter of the fully expanded balloon 
(2.98 f 0.44 mm) suggests ome recoil of the stented 
segment. This minimal recoil appears to ‘be a true phe- 
nomenon since the accuracy and the precision of the 
quantitative coronary angiography system used in this 
study is -30 and 90 CL, respectively.15 Furthermore, re- 
coil has also been observed, although to a larger extent, 
after Wiktor stent implantation in Yorkshire pigs.2o The 
more pronounced recoil (10%) observed in the animal 
model compared with recoil observed in this study (3%) 
may be explained by the fact that in the former animal 
study the stent was implanted in normal coronary arter- 
ies. All these angiographic data indicate that in contrast 
to balloon angioplasty, where recoil amounting to 50% 
has been documented, the Wiktor stent appropriately 
scaffolds the vessel.21 
Restenosis and recurrence of restenosis remains the 
major limitation of (repeat) PTCA. Whether intracoro- 
nary stents can address this issue appropriately is still 
unknown. There are some encouraging data from pre- 
liminary reports.22.23 However, firm conclusions cannot 
be drawn, since these data stem from nonrandomized 
studies in which single and multiple stent implantations 
have been performed in both native coronary arteries 
and venous bypass grafts have been performed in pa- 
tients with either acute ischemic syndromes or stable 
angina for a variety of indications (primary stent im- 
plantation, restenosis, bail out). Patients undergoing re- 
peat PTCA appear to be at a higher risk for recurrence 
of restenosis after repeat intervention. The angiographic 
documented restenosis rate increases from 34% after a 
second dilatation to 40% after a fourth dilatation.6,g 
This is probably an underestimation of the actual inci- 
dence owing to incomplete angiographic follow-up. Re- 
peat angiography is mandatory in all patients, even in 
patients free of angina at follow-up since approximately 
25% of the patients with restenosis are asymptomatic. 
Taking into account the limitations of ,these nonran- 
domized observational studies, as is done in this study, 
the incidence of 29% restenosis using the 50% diameter 
stenosis criterion compares favorably with data from 
those former studies. Indeed, randomized studies are 
needed to define the exact role of intracoronary stenting 
in the prevention of (recurrent) restenosis. 
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